Jacques Theurillat is a Partner at Sofinnova Partners, a Paris-based venture capital firm founded in 1972. See sector focus and contact routes.
Jacques Theurillat is a Partner at Sofinnova Partners, a Paris-based venture capital firm founded in 1972 that specializes exclusively in life sciences, and he leads the firm’s €275 million Sofinnova Crossover I fund. His investment thesis targets late-stage private and public therapeutic companies in the biopharmaceutical and medical device sectors, with a geographic focus on approximately 15 such firms. The Crossover I fund is designed to invest in companies transitioning between private and public markets, though specific check sizes and whether he typically leads or follows are not publicly detailed. Notable portfolio companies where Theurillat holds board or leadership roles include ADC Therapeutics SA, Vifor Pharma AG (where he is Chairman), and Mundipharma, Inc.. He also serves on the boards of Napp Pharmaceutical Holdings Ltd. and CNH Industrial NV, reflecting a broad engagement across pharmaceutical and industrial health entities. While Theurillat has an MBA and graduate degrees from the University of Geneva and Madrid University, there is no publicly available record of distinctive investment viewpoints or published writing attributed to him.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Paris when building a target list.
Investors like Jacques Theurillat · Full investor directory · Investor access · Company funding database